Study guide

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR

Key Takeaways Explain This Topic AI

Maternal physiologic adaptations alter all four pharmacokinetic phases: delayed gastric emptying (absorption), expanded plasma volume by 40–50% reducing hydrophilic drug concentrations (distribution), altered cytochrome P450 and UGT enzymatic clearance (metabolism), and increased GFR by 50% accelerating renal drug elimination.

Serum albumin declines by 20–30% during gestation, decreasing protein binding and increasing the pharmacologically active unbound ('free') fraction of highly bound drugs (e.g., antiepileptic agents); clinicians must monitor free drug levels rather than total concentrations.

Hepatic clearance of lamotrigine increases by up to 300% during pregnancy due to estrogen-mediated UGT1A4 induction, precipitating subtherapeutic drug levels and catastrophic breakthrough seizures unless proactive monthly dose titrations are performed.

In 2015, the FDA Pregnancy and Lactation Labeling Rule (PLLR) eliminated historical letter categories (A, B, C, D, X) in favor of three narrative subsections: 8.1 Pregnancy, 8.2 Lactation, and 8.3 Females and Males of Reproductive Potential.

Established major teratogens exhibit critical gestational susceptibility windows: ACE inhibitors/ARBs trigger 2nd/3rd trimester fetopathy (renal dysgenesis, oligohydramnios, skull hypoplasia), isotretinoin induces 1st trimester retinoic acid embryopathy, and valproic acid causes neural tube defects and neurodevelopmental deficits.

Last updated: October 2026

Gestational Pharmacokinetics: ADME Adaptations

Pregnancy triggers profound physiological adaptations altering drug Absorption, Distribution, Metabolism, and Elimination (ADME). Understanding these changes is critical to maintaining efficacy and preventing maternal-fetal toxicity.

1. Absorption & Bioavailability

Gastrointestinal Motility: Elevated progesterone relaxes gastrointestinal smooth muscle, significantly prolonging gastric emptying and small-intestinal transit time by 30% to 50%. While total drug exposure (Area Under the Curve, AUC) is often preserved, peak serum concentration ( C max C_{\text{max}} C max ​ ) is delayed or blunted.

Gastric Acidity & Emesis: Gastric acid secretion declines while mucus secretion rises, elevating gastric pH and altering the ionization and dissolution of weakly acidic drugs. Hyperemesis gravidarum causes erratic retention and subtherapeutic levels.

2. Distribution & Protein Binding

Fluid Expansion: Maternal plasma volume expands by 40% to 50% (~1,200 to 1,500 mL) alongside a 6 to 8 liter expansion in total body water. This expands the Volume of Distribution ( V d V_d V d ​ ) for hydrophilic drugs (beta-lactams, aminoglycosides, lithium), lowering peak serum levels and requiring higher loading or maintenance doses.

Adipose Accumulation: Maternal fat increases by 3 to 4 kg, expanding V d V_d V d ​ for lipophilic drugs (anesthetics, sedatives, psychotropics) and prolonging elimination half-lives ( t 1 / 2 t_{1/2} t 1/2 ​ ).

Hypoalbuminemia & Unbound Fraction: Serum albumin falls by 20% to 30% (from ~4.0 to ~3.0 g/dL) due to hemodilution. For highly protein-bound medications (>90%, such as phenytoin, valproic acid, carbamazepine, and diazepam), reduced binding capacity substantially increases the unbound, pharmacologically active ('free') drug fraction .

Important

Total vs. Free Drug Levels: Routine assays measure total (bound + unbound) drug concentrations. In pregnancy, total levels of highly protein-bound antiepileptics falsely appear subtherapeutic despite normal or elevated free active concentrations. Increasing doses based on total levels risks severe toxicity; clinicians must monitor free serum concentrations .

3. Hepatic Metabolism & Cytochrome P450 Enzymes

Elevated estrogen and progesterone alter hepatic Cytochrome P450 (CYP) and Phase II enzymes:

Upregulated Enzymes: CYP3A4 activity accelerates clearance of calcium channel blockers, protease inhibitors, and corticosteroids. CYP2D6 activity accelerates clearance of SSRIs (fluoxetine, sertraline) and beta-blockers, often requiring dose increases in the 2nd and 3rd trimesters. CYP2C9 clears phenytoin more rapidly. Estrogen dramatically upregulates UGT1A4: lamotrigine clearance increases by up to 200% to 300% , dropping serum concentrations by 50% to 70% and triggering breakthrough seizures unless monthly levels are monitored and doses titrated.

Downregulated Enzymes: CYP1A2 activity declines by ~50%, prolonging the half-life of caffeine (from 3–5 hours to 10–18 hours in late pregnancy) and theophylline. CYP2C19 metabolism of proton pump inhibitors also declines.

4. Renal Elimination & GFR

Renal blood flow increases by 50% to 80%, and Glomerular Filtration Rate (GFR) rises by 50% beginning in early gestation. Normal pregnancy baseline serum creatinine drops to 0.4 to 0.6 mg/dL (levels ≥0.8 mg/dL flag impairment). Renally eliminated drugs (penicillins, cephalosporins, low-molecular-weight heparins, lithium, digoxin) clear rapidly, requiring larger doses or shortened dosing intervals (e.g., every 8 hours instead of 12 hours).

The FDA Pregnancy & Lactation Labeling Rule (PLLR)

In June 2015, the FDA instituted the PLLR, eliminating the historical letter-category system (A, B, C, D, X). Letter categories were overly simplistic, frequently misread as a safety ranking, and assigned over 65% of prescription drugs to Category C (grouping drugs with proven animal teratogenicity with those lacking data). The letter system also omitted lactation and failed to convey risks across trimesters.

The Three Narrative PLLR Subsections (Labeling Section 8)

8.1 Pregnancy (includes Labor and Delivery):

Pregnancy Exposure Registry: Contact details and web links for registries collecting prospective clinical data.

Risk Summary: Detailed narrative synthesizing human and animal data against the background baseline risk in the U.S. general population (2% to 4% for major congenital malformations, 15% to 20% for miscarriage).

Clinical Considerations: Outlines risks of untreated maternal disease, required gestational dose adjustments, maternal/fetal/neonatal adverse reactions, and labor/delivery management.

Data: Narrative review of human study cohorts and animal toxicology exposure margins.

8.2 Lactation (includes Nursing Mothers):

Risk Summary: Identifies drug presence in human milk, estimated daily infant dose, and the Relative Infant Dose (RID).

Clinical Considerations: Outlines potential adverse effects in the nursing infant requiring monitoring, effects on milk production, and timing strategies to minimize exposure.

Data: Overview of published clinical lactation studies and infant drug levels.

8.3 Females and Males of Reproductive Potential:

Outlines requirements for baseline pregnancy testing, contraception protocols (including duration and washout periods), and drug-induced reversible or irreversible effects on fertility.

Teratogenic Drug Classes, Critical Windows & Syndromes

Teratogenic susceptibility varies by gestational timing: the pre-differentiation "all-or-none" period (weeks 1–2 post-conception; lethal vs. complete recovery), embryonic organogenesis (weeks 3–8 post-conception; major structural malformations), and the fetal period (week 9 to term; growth restriction, functional deficits, or fetopathy).

Teratogenic Class Critical Window Pathologic Phenotype / Fetopathy Clinical Precaution & Safer Alternative

ACE Inhibitors & ARBs (e.g., lisinopril, losartan) 2nd & 3rd trimesters Renal tubular dysgenesis , anuria, severe oligohydramnios , Potter sequence, calvarial skull hypoplasia , perinatal death Strict contraindication in pregnancy (Black Box Warning). Switch to labetalol or nifedipine ER.

Isotretinoin (13-cis-retinoic acid) 1st trimester (25–35% anomaly risk) Retinoic acid embryopathy: Microtia/anotia, stenotic ear canals, cleft palate, conotruncal cardiac defects (tetralogy of Fallot), hydrocephalus, thymic aplasia Strict iPLEDGE REMS protocol: 2 negative pregnancy tests, 2 forms of contraception.

Methotrexate (folic acid antagonist) 1st trimester Aminopterin/methotrexate syndrome: Cranial ossification defects, craniosynostosis, micrognathia, limb reduction defects (syndactyly) Discontinue ≥3 months prior to planned conception; provide high-dose folic acid (4 mg/day).

Valproic Acid (Depakote) 1st trimester Neural tube defects (spina bifida; 1–2% risk, 10× baseline) , facial clefts, cardiac defects, and severe neurodevelopmental deficits / autism / IQ reduction Avoid in reproductive-age females; switch to levetiracetam or lamotrigine with high-dose folic acid (4 mg/day).

Warfarin (Coumadin) Weeks 6 to 9 gestation Fetal warfarin syndrome: Severe nasal hypoplasia , stippled epiphyses (chondrodysplasia punctata), microcephaly, optic atrophy; late intracranial hemorrhage Heparin and LMWH (enoxaparin) do not cross the placenta and are the anticoagulants of choice.

Tetracyclines (doxycycline, minocycline) 2nd & 3rd trimesters (>16 weeks) Chelation with calcium in fetal dentin/enamel: permanent yellow-brown tooth discoloration , enamel hypoplasia; maternal fulminant hepatic necrosis Avoid after 16 weeks; utilize penicillins, cephalosporins, or azithromycin.

Lithium 1st trimester Ebstein anomaly (apical displacement of tricuspid leaflets into right ventricle, severe tricuspid regurgitation, right heart failure) Targeted fetal echocardiography at 18–20 weeks; monitor serum levels closely.